223 related articles for article (PubMed ID: 24559124)
1. The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases.
Toussirot É; Bereau M
Inflamm Allergy Drug Targets; 2014; 13(2):121-7. PubMed ID: 24559124
[TBL] [Abstract][Full Text] [Related]
2. JC Polyomavirus Infection Potentiated by Biologics.
Multani A; Ho DY
Infect Dis Clin North Am; 2020 Jun; 34(2):359-388. PubMed ID: 32444013
[TBL] [Abstract][Full Text] [Related]
3. The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.
Reuwer AQ; Heron M; van der Dussen D; Schneider-Hohendorf T; Murk JL
Acta Neurol Scand; 2017 Nov; 136 Suppl 201():37-44. PubMed ID: 29068484
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
5. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.
Tan CS; Koralnik IJ
Lancet Neurol; 2010 Apr; 9(4):425-37. PubMed ID: 20298966
[TBL] [Abstract][Full Text] [Related]
6. Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy.
Bertoli D; Sottini A; Capra R; Scarpazza C; Bresciani R; Notarangelo LD; Imberti L
Sci Rep; 2019 Nov; 9(1):16605. PubMed ID: 31719595
[TBL] [Abstract][Full Text] [Related]
7. Progressive multifocal leukoencephalopathy.
Weissert R
J Neuroimmunol; 2011 Feb; 231(1-2):73-7. PubMed ID: 20937530
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression increases latent infection of brain by JC polyomavirus.
Bayliss J; Karasoulos T; Bowden S; Glogowski I; McLean CA
Pathology; 2011 Jun; 43(4):362-7. PubMed ID: 21532525
[TBL] [Abstract][Full Text] [Related]
9. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases.
Boren EJ; Cheema GS; Naguwa SM; Ansari AA; Gershwin ME
J Autoimmun; 2008; 30(1-2):90-8. PubMed ID: 18191544
[TBL] [Abstract][Full Text] [Related]
10. Management of infections by the human polyomavirus JC: past, present and future.
Hou J; Major E
Expert Rev Anti Infect Ther; 2005 Aug; 3(4):629-40. PubMed ID: 16107201
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy.
Berger JR
Curr Neurol Neurosci Rep; 2007 Nov; 7(6):461-9. PubMed ID: 17999891
[TBL] [Abstract][Full Text] [Related]
12. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
Cutter GR; Stüve O
Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
[TBL] [Abstract][Full Text] [Related]
13. Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).
Bauer J; Gold R; Adams O; Lassmann H
Acta Neuropathol; 2015 Dec; 130(6):751-64. PubMed ID: 26323992
[TBL] [Abstract][Full Text] [Related]
14. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy.
Bayliss J; Karasoulos T; McLean CA
J Infect Dis; 2013 Jan; 207(1):133-6. PubMed ID: 23112281
[TBL] [Abstract][Full Text] [Related]
16. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
Chahin S; Berger JR
J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
[TBL] [Abstract][Full Text] [Related]
17. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
18. Progressive multifocal leukoencephalopathy: new concepts.
Lima MA
Arq Neuropsiquiatr; 2013 Sep; 71(9B):699-702. PubMed ID: 24141508
[TBL] [Abstract][Full Text] [Related]
19. History and current concepts in the pathogenesis of PML.
Major EO
Cleve Clin J Med; 2011 Nov; 78 Suppl 2():S3-7. PubMed ID: 22123932
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
Tyler KL; Khalili K
Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
[No Abstract] [Full Text] [Related]
[Next] [New Search]